about
Focus on Nivolumab in NSCLCSpecimen acquisition: ROSEs, gardeners, and gatekeepers.Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes.Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist.PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Standardizing biomarker testing for Canadian patients with advanced lung cancer.Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
P2860
Q28073759-D7C90754-ACF2-41BA-B1F5-3BF88E3838A6Q38671527-19111DBF-B555-470E-A550-839387EB34F4Q38673895-EA2D1626-8A75-4DA5-A91E-9C712191C623Q38774259-87429393-890E-441B-9101-8387B12EDDC1Q40496586-7514BA9C-1059-4639-B404-28B98C45D3D8Q42061324-EF786C28-B578-4D51-B59A-A0A0C9E2B347Q42098747-1EEFE192-4EF4-4965-8193-05D3EBF6D46FQ43396965-6E973040-2422-476F-91E3-E68D0F5C59A2Q46990125-3E2F8582-6746-4550-BBBF-A5F90A948CB0Q47104481-2AA2A60C-6BA8-4AF0-AD82-67CD06F59268Q47292249-22F041BA-F6E2-4CCE-8EAB-D7AAD055461EQ48105843-2A1801A4-6375-4194-A226-FBF42F7FD8E4Q48307824-DB051565-8FB4-4C44-B372-8C9C49C83AA9Q48620065-6C2FA897-C0E8-4E44-BC49-18A5696E65B7Q49959323-019FE94C-4354-4876-9FA2-E0C2F85DB8E9Q52673091-19C4507F-9D1B-4976-B141-2941BD53267FQ55318335-EF96201D-36DC-4AB7-8515-FD0BC73C052EQ57821601-4F18FB73-F9EC-454A-A104-A33F8402D194
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
@en
type
label
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
@en
prefLabel
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
@en
P1476
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
@en
P2093
Keith M Kerr
Marianne C Nicolson
P304
P356
10.5858/ARPA.2015-0303-SA
P577
2016-03-01T00:00:00Z